HealthStartNJ LLC invests in study to advance the treatment of neuropathic pain
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact firstname.lastname@example.org
SOURCE New Jersey Health Foundation
PRINCETON, N.J., Oct. 4, 2018 /PRNewswire/ -- HealthStartNJ, established by New Jersey Health Foundation (NJHF) made a financial investment of $50,000 in Paracelsus Neuroscience I, LLC ("Paracelsus"), a startup company founded by Roland G.W. Staal, PhD that focuses on the study and therapeutics of neuropathic pain, announced James M. Golubieski, president of NJHF.
"Neuropathic pain is chronic, pathological pain caused by a lesion of the nervous system resulting in a significant decrease in the quality of life of an affected individual. Recent studies suggest that central and peripheral immune cells may play a significant role in its development and chronicity," explained Dr. Staal.
"Chronic neuropathic pain is very common, however existing treatments offer only limited relief to a minority of patients," explained George F. Heinrich, M.D., vice chair and CEO of HealthStartNJ. "This study by Paracelsus will hopefully one day lead to an effective treatment for the debilitating effects of neuropathic pain."
HealthStartNJ funds health-related research, projects or programs of researchers associated with Kessler Foundation, New Jersey Institute of Technology, Princeton University, Rowan University, Rutgers University and Stevens Institute of Technology.
For more information contact Christine Caruso at (908) 731-6610 or email@example.com.
About New Jersey Health Foundation
New Jersey Health Foundation is a not-for-profit corporation that supports biomedical research and health-related education programs in New Jersey through HealthStartNJ, its Grants Program and its affiliate, Foundation Venture Capital Group which makes private equity investments in life science start- up companies in New Jersey headed toward commercialization.
©2017 PR Newswire. All Rights Reserved.